CELLCHORUS INC.
Biotech · Private
TIMING platform: AI-powered single-cell analysis system using time-lapse imaging and software to track immune cell behavior, phenotype, and metabolism in real time
cellchorus.com →- Grants
- $6.8M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Dynamic single-cell analysis instrument to evaluate immune cell function | $324,340 | |
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Development of arrays to record dynamic interactions between single cells | $274,988 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing | $350,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Dynamic single-cell analysis instrument to evaluate immune cell function | $1,483,544 | |
| Federal grant | Department of Health and Human Services · Phase II · LF-TIMING: Large-scale label-free profiling of cell-cell interactions | $349,171 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing | $984,242 | |
| Federal grant | Department of Health and Human Services · Phase II · Dynamic single-cell analysis instrument to evaluate immune cell function | $462,781 | |
| Federal grant | Department of Health and Human Services · Phase II · Dynamic single-cell analysis instrument to evaluate immune cell function | $56,415 | |
| Federal grant | Department of Health and Human Services · Phase II · LF-TIMING: Large-scale label-free profiling of cell-cell interactions | $1,128,853 | |
| Federal grant | Department of Health and Human Services · Phase I · Functional signatures of post-infusion CAR T cells for early indication of patient response | $399,625 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing | $1,034,752 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3292 | NAVIGEN, INC. | — | — |
| 3293 | Oryn Therapeutics, Inc. | — | — |
| 3294 | Inflamma Therapeutics, LLC | — | — |
| 3295 | CELLCHORUS INC. | — | — |
| 3296 | Viking Therapeutics, Inc. | — | $3.7M |
| 3297 | PHELIX THERAPEUTICS LLC | — | — |
| 3298 | Ferment Labs, Inc. | — | $900K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Systems And Devices For Automated Cellular Profiling And Methods Of Use Thereofapplication
- Systems And Devices For Automated Cellular Profiling And Methods Of Use Thereofapplication
- Systems And Devices For Automated Cellular Profiling And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.